CAM
BIIB icon

Chesapeake Asset Management’s Biogen BIIB Stock Holding History

Chesapeake Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-50
Closed -$11.6K – 526
2024
Q2 		$11.6K Hold
50
– – 0.01% 199
2024
Q1 		$10.8K Hold
50
– – 0.01% 196
2023
Q4 		$12.9K Hold
50
– – 0.01% 222
2023
Q3 		$12.8K Hold
50
– – 0.01% 228
2023
Q2 		$14.2K Hold
50
– – 0.01% 227
2023
Q1 		$13.9K Buy
+50
New +$13.8K 0.01% 218

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Chesapeake Asset Management's BIIB Position: Q3 2024 in Review

Chesapeake Asset Management sold out of Biogen (BIIB) in Q3 2024, closing a stake of 50 shares — an estimated $11.6K sold.

Chesapeake Asset Management first reported a position in BIIB in Q1 2023 and held it in 6 quarters. The position peaked at $14.2K in Q2 2023. 916 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

  • Chesapeake Asset Management reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
  • Chesapeake Asset Management sold 50 Biogen shares in Q3 2024, an estimated $11.6K.
  • Chesapeake Asset Management first reported a position in Biogen in Q1 2023 and held it in 6 quarters.
  • Chesapeake Asset Management's Biogen position peaked at $14.2K in Q2 2023.
  • 916 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Chesapeake Asset Management's 13F filing for Q3 2024, filed 5 Jan 2026.